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290 Oral DHA supplementation in children with cystic ﬁbrosis:
a randomized placebo-controlled study
G. Alicandro1, R. Gagliardini2, B. Santini3, P. Rise’4, A. Bifﬁ1, A.S. Tirelli1,
R.M. Tiso1, L. Valmarana1, N. Cirilli2, C. Colombo1. 1Fond. IRCCS Ca’ Granda
Osp. Maggiore Policlinico, CF Center, Universita` degli studi di Milano, Milan,
Italy; 2CF Center, U.O. Medicina Pediatrica, A.O.U. Ospedali Riuniti “G. Salesi”,
Ancona, Italy; 3CF Center, Centro Pediatrico Pneumologia Pediatrica Ospedale
Regina Margherita, Torino, Italy; 4Universita` degli studi di Milano, Dip. Di
Scienze Farmacologiche, Milano, Italy
Background: Low docosahexaenoic acid (DHA) plasma concentration was reported
in CF patients. Arachidonic acid (AA) is associated with increased proinﬂammatory
eicosanoids, whereas DHA provides antinﬂammatory products.
Aims: To evaluate biochemical and clinical effects of one year DHA supplementa-
tion in CF patients.
Methods: A multicenter double-blind placebo-controlled study was performed.
Thirty-four CF patients aged 6 to 10 years were randomized to receive DHA
(100mg/kg/die in the ﬁrst month and 1 g per day thereafter) or placebo (germ
oil in identical capsules). Plasma fatty acids concentrations were determined by
GLC. Clinical (pulmonary function and anthropometry) and biochemical data
(standard biochemistry, inﬂammatory cytokines, liposoluble vitamins, steatocrit)
were collected every 6 months.
Results: Five patients dropped-out. In the treatment group, but not in the control
group, a signiﬁcant DHA enrichment in plasma (median % of plasma FA from 1.40
up to 4.5%) and a decrease in AA/DHA ratio were documented after 6 months.
Interleukin-8 decreased signiﬁcantly after 6 months but this ﬁnding was not
consistently maintained. No changes in respiratory function, nutritional status and
other biochemical parameters were detected in both groups.
Conclusions: DHA supplementation for one year did not induce any relevant
improvement in CF patients.
291 Home enteral nutrition support in children with cystic ﬁbrosis.
Are all patients the same?
A. Martı´nez-Zazo1, V.M. Navas-Lo´pez2, C. Martı´nez-Costa3, F. Sa´nchez-
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Objectives and Study: The aim of this study was to analyze the results of the
NEPAD register, a Spanish multicentre on-line register of home enteral nutrition
(HEN), regarding to patients with cystic ﬁbrosis (CF).
Methods: Recompilation of the data from the NEPAD register from January 2003
to October 2010.
Results: 49 patients were included. The median age of HEN support was
3.16 years (y) (IQR 0.74−9.7). The ﬁrst enteral access was the nasogastric tube
(NGT) in 49% of the children followed by gastrostomy (G, 42.9%). Children
with NGT were signiﬁcant younger at the beginning of HEN than patients with
G (p = 0.01). 85.7% of the children used enteral nutrition pumps. The cyclic
administration method was the most frequent (65.3%). Homemade food was used
in 14.3% of the patients with G and in 5.3% of the cases with NGT (c2, p< 0.001).
Enteral formulas were used in 91.8% of the patients, only 11% of patients received
enteral formula and homemade foods; the most common formula (30.6%) was
paediatric polymeric followed by adult formula. Nutritional support concluded in
61.2% of the patients [median 1.03 y (IQR 0.13–2.30)], in 60% of the cases the
cessation was because transition to oral feeding. The mean duration of HEN was
signiﬁcantly higher in patients with G versus NGT carriers (p = 0.0001).
Conclusion: CF patientsrequiring nutritional support are clearly divided into 2 pop-
ulations: younger patients tend to use NGT for a short period of time and in
older patients the G is often used for more prolonged periods of time. The cyclic
administration method is the most frequent used in these patients in order to preserve
the oral feeding. Most patients used enteral formulas.
292 A retrospective audit of growth and lung function in patients
with cystic ﬁbrosis (CF) undergoing gastrostomy insertion with
fundoplication over a 10 year period
P. Beadle1, K. Brownlee1, T. Lee1, S. Wolfe1, A. Najmaldin1. 1Leeds Childrens’
Hospital, Regional Paediatric CF Unit, Leeds, United Kingdom
Poor nutrition and gastro-esophageal reﬂux are signiﬁcant problems in some
children with CF. Gastrostomy feeding is often used to provide long term nutritional
support, however in some patients, problems with reﬂux can compromise safety,
lung function and weight gain. In Leeds all children referred for a gastrostomy
are routinely investigated for evidence of reﬂux and if present a fundoplication is
advised. The aim of this study is to investigate the change in growth and respiratory
function (RF) in patients before and following these procedures.
Method: Retrospective Wt, Ht, BMI Standard Deviation Scores (SDS) and RF data
was collected for all children with CF who had a gastrostomy and fundoplication
between May 1996 and May 2007. Data was collected at six monthly intervals
18 months prior to surgery, at surgery and at six monthly intervals for 36 months
post surgery.
Results: 16 patients (8M), mean age at surgery 10.3 years (4.7–15.4) had both a
gastrostomy and fundoplication. Growth data was available for all 16 children. The
mean change in Wt and Ht SDS per month post surgery was signiﬁcantly better
than the change per month prior to surgery. (Mean monthly change in Wt and
Ht SDS pre surgery −0.01, −0.01 and post surgery 0.02, 0.01. p< 0.01, p< 0.05
respectively.) The change in BMI did not reach signiﬁcance (p = 0.057) For the
12 children RF data were available, there was no signiﬁcant change in mean lung
function per month in the 36 months post surgery when compared to the 18 months
prior to surgery.
Conclusion: Gastrostomy and Fundoplication in children with CF signiﬁcantly
improves weight and height gain but does not signiﬁcantly improve BMI or %
predicted RF.
293 Administration of CREON® pellets via gastrostomy tube (G-Tube)
without loss of gastric resistance or lipase activity
G. Shlieout1, A. Koerner1, M. Maffert1, K. Forssmann1, S. Caras2. 1Abbott,
Hannover, Germany; 2Abbott, Marietta, United States
Objective: In clinical practice, the need often arises to administer CREON (capsules
containing pancreatin gastro-resistant pellets) by G-tube. Our aim was to identify
G-tubes that allow administration of CREON pellets without clogging, sticking,
pellet damage, or loss of integrity.
Methods: In this in vitro study, CREON capsules were opened, pellets sprinkled
onto baby food pH <4.5 (applesauce and bananas of 2 different brands), stirred
gently, then using a syringe pushed slowly (~15 cc in 10−15 s) through G-tubes
of different types/sizes. G-tubes were visually inspected for clogging, sticking, and
pellet damage. If there was none with all 4 foods, pellet integrity (gastric resistance,
lipase activity) was tested by an in vitro dissolution method modiﬁed from USP
and PhEur monographs (2-h gastric simulation step). Integrity was considered
maintained at 80% actual lipase activity per capsule at end of this step.
Results: There was no clogging, sticking, or visible pellet damage, and integrity
was maintained when administering CREON through these G-tubes: Kimberly-
Clark MIC Bolus® size 18 Fr and MIC-KEY® 16 Fr; Bard® Tri-Funnel 18 Fr and
Button 18 Fr. Released lipase activity exceeded the pre-determined threshold in
all cases (>80% relative to actual lipase activity), with no differences vs untreated
pellets. The results are applicable to all CREON capsule strengths as composition
and quality are identical.
Conclusion: CREON pellets can be mixed with baby food pH <4.5 and adminis-
tered via the following G-tubes without loss of gastric resistance or lipase activity:
Kimberly-Clark MIC Bolus 18 Fr and MIC-KEY 16 Fr; Bard Tri-Funnel 18 Fr
and Button 18 Fr.
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